Patents Assigned to Almirall, S.A.
  • Pharmaceutical compositions comprising dimethyl fumarate
    Patent number: 11602515
    Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastroresistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 14, 2023
    Assignee: Almirall, S.A.
    Inventor: Jorge Aubets Mir
  • COMPOSITIONS COMPRISING TIMOLOL AND THEIR USE IN THE TREATMENT OF ROSACEA BY TOPICAL ADMINISTRATION
    Publication number: 20210220368
    Abstract: The present invention relates to the use of timolol in treating rosacea, and to pharmaceutical compositions comprising timolol.
    Type: Application
    Filed: June 15, 2017
    Publication date: July 22, 2021
    Applicant: Almirall, S.A.
    Inventors: Bernat Vidal Juan, Maria Victoria Revilla Sanchez, Gema Tarrason Encuentra
  • Dosage and formulation
    Patent number: 11000517
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: May 11, 2021
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors
    Patent number: 10759793
    Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 1, 2020
    Assignee: Almirall, S.A.
    Inventors: Cristina Esteve Trias, Joan Taltavull Moll, Jacob Gonzalez Rodriguez, Bernat Vidal Juan
  • Pharmaceutical Compositions Comprising Dimethyl Fumarate
    Publication number: 20200197348
    Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastroresistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
    Type: Application
    Filed: June 25, 2018
    Publication date: June 25, 2020
    Applicant: Almirall, S.A.
    Inventor: Jorge AUBETS MIR
  • Combinations comprising MABA compounds and corticosteroids
    Patent number: 10456390
    Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: October 29, 2019
    Assignee: Almirall, S.A.
    Inventors: Monica Aparici Virgili, Marta Calbet Murtro, Montserrat Miralpeix Guell, Amadeu Gavalda Monedero, Carlos Puig Duran
  • COMPOSITIONS COMPRISING TIMOLOL AND AN ANTI-INFLAMMATORY AGENT
    Publication number: 20190231788
    Abstract: The present invention relates to combinations comprising timolol and a compound useful for the treatment of rosacea selected from ivermectin, metronidazole and praziquantel and to the use of these combinations in the topical treatment of rosacea.
    Type: Application
    Filed: June 15, 2017
    Publication date: August 1, 2019
    Applicant: Almirall, S.A.
    Inventors: Nuria Godessart Marina, Gema Tarrason Encuentra
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 10300072
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 28, 2019
    Assignee: Almirall, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Amino-substituted heterocyclic derivatives as sodium channel inhibitors
    Patent number: 10214509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 26, 2019
    Assignee: Almirall, S.A.
    Inventors: James Duffy, Mark Stuart Chambers, Alastair Rae, James Osborne, Isabelle Anne Lemasson, Michael Daniel Goldsmith, Andrew Sharpe, Silvia Fonquerna Pou
  • Aminoindazole derivatives as sodium channel inhibitors
    Patent number: 10173985
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav 1.7, to compositions containing said derivatives and processes for their preparation.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: January 8, 2019
    Assignee: Almirall, S.A.
    Inventors: Laia Sole Feu, Silvia Fonquerna Pou
  • Dosage and formulation
    Patent number: 10085974
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 2, 2018
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • Bicyclic derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 10005771
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 26, 2018
    Assignee: Almirall, S.A.
    Inventors: Carlos Puig Duran, Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quiñones
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 9757383
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: September 12, 2017
    Assignee: Almirall, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Aclidinium for use in improving the quality of sleep in respiratory patients
    Patent number: 9737520
    Abstract: The present disclosure provides aclidinium or any of its stereoisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 22, 2017
    Assignee: Almirall, S.A.
    Inventors: Maria Esther Garcia Gil, Gonzalo De Miquel Serra, Maria Jose Sala Peinado
  • Cyclohexylamine derivatives having ?2 adrenergic antagonist and M3 muscarinic antagonist activities
    Patent number: 9643961
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 9, 2017
    Assignee: Almirall, S.A.
    Inventors: Maria Prat Quinones, Silvia Fonquerna Pou, Carlos Puig Duran, Wenceslao Lumeras Amador, Jose Aiguade Bosch, Juan Francisco Caturla Javaloyes
  • Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities
    Patent number: 9579316
    Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: February 28, 2017
    Assignee: Almirall, S.A.
    Inventors: Montserrat Julia Jane, Francesc Carrera Carrera, Maria Prat Quiñones, Carlos Puig Duran, Francesca Pajuelo Lorenzo, Juan Antonio Perez Andres
  • Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both ?2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities
    Patent number: 9562039
    Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: February 7, 2017
    Assignee: Almirall, S.A.
    Inventors: Montserrat Julia Jane, Francesc Carrera Carrera, Maria Prat Quiñones, Carlos Puig Duran, Francesca Pajuelo Lorenzo, Juan Antonio Perez Andres
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 9549934
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 24, 2017
    Assignee: Almirall, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Cyclohexyl and quinuclidinyl carbamate derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activity
    Patent number: 9518050
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: December 13, 2016
    Assignee: Almirall, S.A.
    Inventors: Laia Sole Feu, Ines Carranco Moruno, Jose Aiguade Bosch, Carlos Puig Duran, Silvia Fonquerna Pou
  • Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
    Patent number: RE46417
    Abstract: A compound according to formula (I) wherein: © is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; which shows high affinity for muscarinic M3 receptors (Hm3).
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 30, 2017
    Assignee: Almirall, S.A.
    Inventors: Dolors Fernandez Forner, Maria Prat Quiñones, Maria Antonia Buil Albero